JAK2 Mutation Detection Using Targeted Exon 12-15 Analysis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods fail to accurately identify specific mutations in the JAK2 gene associated with hematopoietic diseases such as myeloproliferative disorders, which are characterized by an aberrant increase in blood cells, leading to conditions like polycythemia vera, essential thrombocythemia, and chronic idiopathic myelofibrosis, and these mutations contribute to the pathogenesis of these diseases.
Innovation Solution
The invention identifies previously unknown mutations in the JAK2 gene and protein, providing compositions and methods for diagnosing and prognosing hematopoietic diseases by evaluating samples for the presence of these mutations using nucleic acid and polypeptide analysis, including amplification and hybridization techniques for nucleic acid and antibody-based detection for polypeptides.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current diagnostic methods are used, then general blood cell analysis can be performed, but specific JAK2 mutations cannot be accurately identified
Solution Approach 1:
The patent segments the JAK2 gene into specific exons (exons 12-15) for targeted analysis. By dividing the gene into manageable sections and focusing on specific regions known to contain mutations, the method achieves precise mutation detection while reducing the complexity of analyzing the entire gene sequence.
Solution Approach 2:
The patent applies local quality by focusing detection efforts on specific regions of the JAK2 gene where mutations are most likely to occur (exons 12-15). This targeted approach concentrates measurement precision on the most critical areas rather than uniformly analyzing the entire gene, thereby improving detection accuracy without proportionally increasing overall complexity.
2Reliability
If comprehensive mutation screening is performed, then disease diagnosis accuracy improves, but test complexity and time increase
Solution Approach 1:
The patent performs preliminary action by pre-identifying and focusing on the most likely mutation sites (exons 12-15) before comprehensive analysis. This allows the testing protocol to systematically address the most critical regions first, improving diagnosis accuracy for the most common mutations while managing test complexity through a structured, prioritized approach.
Solution Approach 2:
The patent applies partial action by screening only the most relevant exons (12-15) rather than the entire JAK2 gene. This selective approach provides sufficient diagnostic accuracy for the majority of cases while reducing the overall complexity and time required for testing, avoiding the excessive action of analyzing every possible region.
3Reliability
If multiple JAK2 mutations are screened, then disease prognosis improves, but detection difficulty increases
Solution Approach 1:
The patent merges multiple mutation detection strategies into a unified approach focused on exons 12-15. By combining various detection methods (sequencing, real-time PCR, allele-specific oligonucleotide hybridization) within this specific region, the system can simultaneously screen for multiple mutations without proportionally increasing detection difficulty, as all methods target the same critical regions.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables accurate diagnosis and prognosis of hematopoietic diseases by identifying specific JAK2 mutations, allowing for targeted therapy selection and predicting disease progression.
Implementation Method 1
evaluating samples for the presence of these mutations using nucleic acid and polypeptide analysis, including amplification and hybridization techniques for nucleic acid
Implementation Method 2
amplification and hybridization techniques for nucleic acid
Data Source
AI summary
The invention disclosed herein is based on the identification of novel mutations in the JAK2 gene and JAK2 protein. The invention provides compositions and methods useful for diagnosing hematopoietic diseases including, for example, myeloproliferative diseases. The invention also provides compositions and methods useful for determining a prognosis of an individual diagnosed as having a hematopoietic disease.